Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 23108951)

1.

Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane.

Guerrero A, Gavilá J, Folkerd E, Ortiz B, Martínez F, García A, Climent MA, Guillem V, Ruíz A.

Ann Oncol. 2013 Mar;24(3):674-9. doi: 10.1093/annonc/mds464. Epub 2012 Oct 28.

2.

Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.

Dieudonné AS, Vandenberghe J, Geerts I, Billen J, Paridaens R, Wildiers H, Neven P.

Menopause. 2011 Jul;18(7):821-4. doi: 10.1097/gme.0b013e318204af88.

PMID:
21326118
3.

Impact of chemotherapy-induced amenorrhea in breast cancer patients: the evaluation of ovarian function by menstrual history and hormonal levels.

Meng K, Tian W, Zhou M, Chen H, Deng Y.

World J Surg Oncol. 2013 May 20;11:101. doi: 10.1186/1477-7819-11-101.

4.
5.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group.

N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1.

6.

Predictors of recovery of ovarian function during aromatase inhibitor therapy.

Henry NL, Xia R, Banerjee M, Gersch C, McConnell D, Giacherio D, Schott AF, Pearlman M, Stearns V, Partridge AH, Hayes DF.

Ann Oncol. 2013 Aug;24(8):2011-6. doi: 10.1093/annonc/mdt149. Epub 2013 Apr 23.

7.

Tamoxifen and ovarian function.

Berliere M, Duhoux FP, Dalenc F, Baurain JF, Dellevigne L, Galant C, Van Maanen A, Piette P, Machiels JP.

PLoS One. 2013 Jun 28;8(6):e66616. doi: 10.1371/journal.pone.0066616. Print 2013.

8.

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.

Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, Gonnelli S.

Br J Cancer. 2006 Jul 17;95(2):153-8.

9.

Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.

Fontein DB, Seynaeve C, Hadji P, Hille ET, van de Water W, Putter H, Kranenbarg EM, Hasenburg A, Paridaens RJ, Vannetzel JM, Markopoulos C, Hozumi Y, Bartlett JM, Jones SE, Rea DW, Nortier JW, van de Velde CJ.

J Clin Oncol. 2013 Jun 20;31(18):2257-64. doi: 10.1200/JCO.2012.45.3068. Epub 2013 Apr 22.

10.

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.

Bertelli G, Hall E, Ireland E, Snowdon CF, Jassem J, Drosik K, Karnicka-Mlodkowska H, Coombes RC, Bliss JM.

Ann Oncol. 2010 Mar;21(3):498-505. doi: 10.1093/annonc/mdp358. Epub 2009 Aug 28.

11.

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.

Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C; Intergroup Exemestane Study.

N Engl J Med. 2004 Mar 11;350(11):1081-92. Erratum in: N Engl J Med. 2004 Dec 2;351(23):2461. N Engl J Med. 2006 Oct 19;355(16):1746. van de Velde, Cornelius [added].

12.

Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.

Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJ, Lønning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RC.

J Clin Oncol. 2012 Mar 1;30(7):709-17. doi: 10.1200/JCO.2010.33.7899. Epub 2011 Oct 31.

13.

Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.

Smith IE, Dowsett M, Yap YS, Walsh G, Lønning PE, Santen RJ, Hayes D.

J Clin Oncol. 2006 Jun 1;24(16):2444-7.

14.

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.

Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P.

J Clin Oncol. 2008 Oct 20;26(30):4883-90. doi: 10.1200/JCO.2007.14.4659. Epub 2008 Sep 15.

15.

[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].

van Nes JG, Seynaeve C, van de Velde CJ, Nortier JW.

Ned Tijdschr Geneeskd. 2006 Dec 30;150(52):2863-9. Review. Dutch.

PMID:
17319217
16.

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study.

Lancet. 2007 Feb 17;369(9561):559-70. Erratum in: Lancet. 2007 Mar 17;369(9565):906.

PMID:
17307102
17.

Adjuvant ovarian suppression in premenopausal breast cancer.

Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; SOFT Investigators; International Breast Cancer Study Group.

N Engl J Med. 2015 Jan 29;372(5):436-46. doi: 10.1056/NEJMoa1412379. Epub 2014 Dec 11.

PMID:
25495490
18.

Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer.

Torino F, Barnabei A, De Vecchis L, Appetecchia M, Strigari L, Corsello SM.

Endocr Relat Cancer. 2012 Apr 10;19(2):R21-33. doi: 10.1530/ERC-11-0199. Print 2012 Apr. Review.

19.

Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.

Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE.

J Clin Oncol. 2012 Feb 10;30(5):533-8. doi: 10.1200/JCO.2011.34.6890. Epub 2012 Jan 9.

20.

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

Gibson LJ, Dawson C, Lawrence DH, Bliss JM.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003370. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD003370.

PMID:
17253488
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk